2021-12-13 - Cancer Synoptic Reporting Project Group Meeting

1. Three types of intactness of interest in synoptics
   1. Mesorectum (completeness)
   2. Others (ovary, fallopian tubes, uterus) - ruptured, morcelated, etc
   3. IHC nuclear staining

1. Suggest that we leave these concepts as primitive for now. Too much time being spent on low priority items?

1. Two use cases:
   
   
   1. Prognostic stains - Primary cancer already determined.  Used for treatment decisions to be made.
      1. Pathologists knows where stain will/will not be expressed
      2. No need to declare location within cell that expresses the stain (nucleus, cytoplasm, membrane)
         
         
   2. Diagnostic stains - Used to differentiate between possible diagnoses.
      1. Where the protein is expressed informs the pathologist needed information to render a diagnosis.
      2. Need to declare location of protein expression in the cell.

What are we measuring when assessing "treatment effect"?  

Is this a histologic change?  Viability of tumor cells?